Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 10 от 222

Набира участници Фаза 3

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

Trial status: Authorised Overall Survival (OS), Distant Metastasis-Free Survival (DMFS), Lung Cancer Specific Survival (LCSS), Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score, Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score, Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score, Change from Baseline in the EORTC-QLQ-C30 Dyspnea (Item 8) Score, Change from Baseline in the EORTC-Quality of Life Questionnaire-Lung Cancer 24 (QLQ-LC24) Coughing (Items 31 and 52) Combined Score, Change from Baseline in the EORTC-QLQ-LC24 Chest Pain (Item 40) Score, Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE Disease-Free Survival (DFS)

Начало: 20.04.2026 Възраст: от 18 г.

France, Germany, Greece +1 Merck Sharp & Dohme LLC 2024-517337-41-00

Набира участници Фаза 2

An autologous and antigen-specific cell-based therapy of vitamin D3-treated and myelin-derived peptide loaded tolerogenic dendritic cells in subjects with progressive forms of multiple sclerosis: a phase IIa, open-label, self-controlled, multi-center clinical trial.

Multiple Sclerosis

Trial status: Authorised Neurological examinations will be complemented with two validated functional tests: the 9-HPT for arm dexterity and the SDMT for cognitive performance. The impact on disability progression will be analyzed by the proportion of participants free from confirmed disability progression, Various MRI measures will be followed for safety and efficacy via the number of new and/or enlarging T2 lesions, total brain volume and brain atrophy., Change in Neurofilament Light Chain (NfL) serum and Glial Fibirallary Acidic Protein (GFAP) serum will be assessed as biomarkers, Tertiary end point: To comprehensively assess therapy-related immunological changes and the induction of antigen-specific tolerance, we will perform high-dimensional immune profiling using cryopreserved peripheral blood mononuclear cells (PBMCs) and matched serum/plasma samples collected at predefined time points throughout the trial., Tertiary end point: Participants will report their pain experience using a VAS. Quality of life will be measured using the EQ-5D-5L questionnaire. Evaluate the efficacy of tolDC administration by assessing the change in Expanded Disability Severity Scale (EDSS) score., To assess the safety the tolerability of tolDC administration will be assessed by recording the incidence, severity, and relationship to study treatment of adverse events throughout the trial.

Начало: 20.04.2026 Възраст: 18–64 г.

Belgium Universitair Ziekenhuis Antwerpen, Hospital Germans Tri 2025-522040-40-01

Набира участници Фаза 3

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

severe to moderately severe hemophilia B (FIX:C ≤ 2%) hemophilia A

Trial status: Authorised Total ABR (treated and untreated), Incidence of and time from previously administered gene therapy infusion to resumption of prophylaxis, AIR of exogenous factor, Consumption of exogenous factor, Incidence of Non-hepatic malignancy, Incidence of Auto-immune disorders, Incidence of SAEs, All cause-mortality, EQ-5D-5L dimension and VAS scores Incidence of thromboembolic events, Incidence of factor inhibitor development, Incidence of hepatic malignancy, Incidence of liver abnormalities, Factor activity level

Начало: 20.04.2026 Възраст: 18–64 г.

Greece, Sweden Pfizer Inc. 2025-523660-21-00

Набира участници Фаза 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Trial status: Authorised Overall survival at Week 96, Change from baseline through Week 26, Week 48 in Speaking rate as measured by quantitative speech assessment in the clinic. Change from baseline through Week 48 in Intelligibility of speech as measured by quantitative speech assessment in the clinic., Change from baseline through Week 48 in percent predicted slow vital capacity, Change from baseline through Week 48 in the Bulbar subdomain of the ALSFRS-R, Change from baseline through Week 48 in the ALSAQ-40, Incidence, nature, and severity of treatment emergent adverse events, adverse events of special interest, and serious adverse events. Incidence and shifts of clinically significant abnormalities in ECG, laboratory tests, and vital signs. Change from baseline in C-SSRS. Tolerability. Change from baseline through Week 26 in the ALSFRS-R total score adjusted for mortality. Change from baseline through Week 48 in the ALSFRS-R total score adjusted for mortality.

Начало: 20.04.2026 Възраст: от 18 г.

Germany, Italy, Netherlands +3 Ferrer Internacional S.A., Prilenia Therapeutics B.V. 2025-524002-16-00

Набира участници Фаза 3

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

Carcinoma Transitional Cell Urinary Bladder Neoplasms Neoplasm Metastasis

Trial status: Authorised Safety Lead-in:Safety and Tolerability of vepugratinib in combination with EV and pembrolizumab, Safety Lead-in:Overall Response Rate (ORR), Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)

Начало: 20.04.2026 Възраст: от 18 г.

Czech Republic, Denmark, Germany +4 Eli Lilly & Co. 2025-522855-25-00

Набира участници Фаза 3

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).

Начало: 20.04.2026 Край: 05.07.2029 Възраст: от 18 г.

China Qilu Pharmaceutical Co., Ltd. NCT07463573

Набира участници

Knee Osteoarthritis Rehab: High-Intensity Laser vs Classical Modalities

Knee Arthritis Osteoarthritis

This study aims to compare the effectiveness and safety of High-Intensity Laser Therapy (HILT) with conventional physical therapy treatments in patients with knee osteoarthritis. Knee osteoarthritis is a common condition, especially in older adults, causing pain, stiffness, reduced movement, and difficulty performing daily activities. Current treatments focus on reducing pain and improving joint function. In this study, 100 patients with knee osteoarthritis will be divided into two groups. One group will receive HILT combined with therapeutic exercises, while the other group will receive conventional physical therapy modalities along with the same exercises. The treatment outcomes will be evaluated over time. The main outcomes include pain reduction (measured by pain scales such as WOMAC and VAS), improvement in joint function, and structural changes in the knee assessed by MRI. In addition, laboratory tests will be used to measure inflammation, cartilage health markers, and oxidative stress before and after treatment. The goal is to determine whether HILT provides better pain relief, improves joint function, and is safe compared to standard therapy. The results may help improve rehabilitation strategies for patients with knee osteoarthritis.

Начало: 20.04.2026 Край: 20.01.2027 Възраст: 30–60 г.

Iraq Erbil Polytechnic University NCT07551245

Набира участници

Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton

Acquired Brain Injury (Including Stroke) Spinal Cord Injury Multiple Sclerosis

The primary objective of this study is to validate the safety and clinical performance of the ABLE Exoskeleton with integrated Functional Electrical Stimulation (ABLE FES) in individuals with neurological conditions that impair gait, including spinal cord injury, acquired brain injury, and multiple sclerosis. The secondary objective is to collect preliminary data on the potential clinical and psychosocial benefits of combining robotic gait assistance with electrical stimulation.

Начало: 20.04.2026 Край: 12.08.2026 Възраст: 18–80 г.

Austria ABLE Human Motion S.L. NCT07550699

Набира участници

Exploration of the Functional Effect of Modified Gain Precalculation on Soft Speech Intelligibility

Hearing Loss

An exploratory investigation of gain precalculation principles in CE-labelled Sonova brand hearing instruments (e.g. Phonak hearing instruments) is intended to be conducted on hearing impaired participants. These gain precalculation principles are enabled by respective hearing instrument technologies and hearing instrument algorithms. The aim of the study is to investigate and assess strength and weaknesses of these gain precalculation principles in terms of speech intelligibility to determine their application in hearing instruments (Phase of development). Objective laboratory measurements as well as subjective ratings will be carried out. This will be a controlled, single blinded and randomized active comparator clinical evaluation which will be conducted mono centric at Sonova AG Headquarter based in Stäfa.

Начало: 20.04.2026 Край: 30.05.2026 Възраст: 18–99 г.

Switzerland Sebastian Griepentrog NCT07388784

Набира участници

Sauna for Offline Connections and Interactive, Authentic Living

Loneliness

This pilot trial will test an intervention (sauna visits) targeting reductions in loneliness in adults aged 19-22 years. Participants will: * Visit a sauna in San Francisco once per week for 2 hours by themselves or with a friend, for 8 weeks total * Complete online surveys throughout their participation The main question this pilot trial aims to answer are: * To what extent do participants find the study design acceptable? * To what extent do participants complete the weekly sauna visits? * To what extent do participants complete the weekly online surveys?

Начало: 20.04.2026 Край: 30.03.2027 Възраст: 19–22 г.

United States University of California, San Francisco NCT07223099

Набира участници Фаза 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Acute Severe Ulcerative Colitis

This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can upadacitinib as a second-line therapy effectively induce remission in acute severe ulcerative colitis with efficacy non-inferior to infliximab? (2) What adverse reactions may occur with upadacitinib in the treatment of acute severe ulcerative colitis? Researchers will also compare the efficacy of upadacitinib with that of corticosteroids to assess its therapeutic effect. Participants will be assigned to either the upadacitinib group (receiving upadacitinib extended-release tablets 45 mg once daily for 8 weeks, followed by 30 mg once daily) or the infliximab group (receiving an initial dose of 5 mg/kg, with additional doses at week 2, week 6, and every 8 weeks thereafter at the same dose). The treatment duration is 3 months, with outpatient visits for examinations and tests every two weeks. Patients will record their bowel movements and symptoms such as abdominal pain, and undergo colonoscopy, ultrasound examinations, and blood tests at specified time points.

Начало: 20.04.2026 Край: 01.11.2028 Възраст: 18–85 г.

China Xijing Hospital of Digestive Diseases NCT07550673

Набира участници Фаза 1

A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

Healthy participants and participants with type 2 diabetes

Trial status: Authorised

Начало: 19.04.2026 Възраст: 18–64 г.

Austria Novo Nordisk A/S 2025-523304-68-00

Набира участници

Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty

Analgesic Efficacy Quadro-Iliac Plane Block Erector Spinae Plane Block Total Hip Arthroplasty

This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.

Начало: 18.04.2026 Край: 01.10.2026 Възраст: от 18 г.

Egypt Tanta University NCT07537036

Набира участници

Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General Anesthesia

Sublingual Caffeine Recovery Time Postoperative Agitation +2

This study aims to evaluate the efficacy of sublingual caffeine in reducing recovery time and incidence of postoperative agitation in elderly patients undergoing general anesthesia.

Начало: 18.04.2026 Край: 30.08.2026 Възраст: от 65 г.

Egypt Cairo University NCT07536568

Набира участници

Prediction of Rectus Femoris Graft Size in ACL Reconstruction

Anterior Curciate Ligament

This study aims to develop and validate a predictive model for estimating the diameter of a quadrupled rectus femoris tendon graft used in anterior cruciate ligament (ACL) reconstruction. By analyzing patient anthropometric characteristics and intraoperative tendon measurements, we aim to identify reliable predictors of graft size to improve preoperative planning and surgical decision-making.

Начало: 18.04.2026 Край: 30.08.2026 Възраст: от 18 г.

Turkey (Türkiye) Samsun University NCT07538245

Набира участници

The Effect of Muscle Stimulation and Amino Acid Intake on Protein Metabolism During Critical Illness

Muscle Wasting in Critically Ill

The goal of this clinical trial is to study how whole-body electrical stimulation combined with amino acid intake affects muscle health in ventilated ICU patients. The main questions to answer are: * Does electrostimulation improve the balance of muscle protein in ICU patients? * Does combining electrostimulation with amino acid help build muscle and prevent muscle loss? Researchers will compare three groups of patients: 1. Sham electrostimulation (no current applied) + the standard nutrition 2. Electrostimulation + the standard nutrition 3. Electrostimulation + a 20g amino acid bolus Participants will: * Receive either real or sham electrostimulation * Get their standard nutrition or a 20g amino acid bolus * Have marked amino acids given through an IV * Have blood samples taken to measure the amino acids and glucose in the blood * Undergo ultrasound of the upper arm to measure the blood flow

Начало: 18.04.2026 Край: 01.12.2027 Възраст: от 18 г.

Netherlands Wageningen University NCT07430969

Набира участници

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

HIV Menopause Cardiovascular (CV) Risk Carotid Arteriosclerosis +1

Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.

Начало: 17.04.2026 Край: 01.03.2030 Възраст: от 18 г.

United States University of California, San Francisco NCT07284082

Набира участници

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

Cervical Cancer HPV Infection

This study is testing and implementing an equity-focused, community-based intervention that improves women's access to cervical cancer screening and adherence to follow up after an abnormal result. The study's objective is to assess and compare the feasibility of different methods of distributing at-home HPV testing kits for cervical cancer screening among individuals who are under-screened.

Начало: 17.04.2026 Край: 15.01.2028 Възраст: 25–65 г.

United States Washington University School of Medicine NCT07453459

Набира участници Фаза 2

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)

This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).

Начало: 17.04.2026 Край: 14.04.2029 Възраст: от 18 г.

China Fudan University NCT07536789

Набира участници

Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Treatment of Adenomyosis-related Abnormal Uterine Bleeding

Abnormal Uterine Bleeding Due to Adenomyosis (Disorder)

The present study aims to compare the efficacy (menstrual blood loss, pain, quality of life) and the safety (complications, recovery) of each conservative intervention (RFA, UAE) versus hysterectomy for the treatment of adenomyosis-related abnormal uterine bleeding, up to 2 years

Начало: 17.04.2026 Край: 01.05.2029 Възраст: 30–50 г.

France University Hospital, Bordeaux NCT07195305

1 … 8 9 10 11 12 … 222